Bland Embolization Versus Chemoembolization of Hepatocellular Carcinoma Before Transplantation

Size: px
Start display at page:

Download "Bland Embolization Versus Chemoembolization of Hepatocellular Carcinoma Before Transplantation"

Transcription

1 LIVER TRANSPLANTATION 20: , 2014 ORIGINAL ARTICLE Bland Embolization Versus Chemoembolization of Hepatocellular Carcinoma Before Transplantation Michael D. Kluger, 1 Karim J. Halazun, 1 Ryan T. Barroso, 1 Alyson N. Fox, 5 Sonja K. Olsen, 5 David C. Madoff, 6 Abby B. Siegel, 2 Joshua L. Weintraub, 3 Jonathan Sussman, 3 Robert S. Brown Jr, 4 Daniel Cherqui, 1 and Jean C. Emond 1 1 Department of Surgery, 2 Division of Hematology and Oncology, Department of Medicine, 3 Division of Interventional Radiology, Department of Radiology, and 4 Section of Digestive and Liver Diseases, Department of Medicine, NewYork Presbyterian Hospital/Columbia Presbyterian Medical Center, New York, NY; and 5 Section of Digestive and Liver Diseases, Department of Medicine, and 6 Division of Interventional Radiology, Department of Radiology, NewYork Presbyterian Hospital/Weill-Cornell Medical Center, New York, NY There is conflicting literature regarding the superiority of transarterial chemoembolization (TACE) versus bland transarterial embolization (TAE), and this has not been well studied before transplantation. Twenty-five TAE patients were matched in a 1:2 ratio with TACE patients by the initial radiographic tumor size and number in a retrospective, case-controlled study. The patients were otherwise treated according to the same protocols. The method of embolization was chosen on the basis of interventionalist practices at 2 sites within the program. Kaplan-Meier survival analyses at 1 and 3 years were the primary endpoints. There were no significant demographic differences between the groups. The mean adjusted Model for End- Stage Liver Disease scores at transplantation and waiting times were not significantly different between the TAE and TACE patients (MELD scores: versus points, P ; waiting times: versus months, P ). TAE patients (16%) were less likely than TACE patients (40%) to require 2 procedures (P ). Explant tumors were completely necrotic for 36% of the TAE patients and for 26% of the TACE patients. The 3-year overall survival rates were 78% for the TAE patients and 74% for the TACE patients (P ), and the 3-year recurrence-free survival rates were 72% for the TAE patients and 68% for the TACE patients (P ). On an intention-to-treat basis, there was no significant risk of wait-list dropout associated with TAE or TACE (P ). In conclusion, there were no significant differences in wait-list dropout or in overall or recurrence-free survival between HCC patients undergoing TAE and HCC patients undergoing TACE before transplantation. Liver Transpl 20: , VC 2014 AASLD. Received March 5, 2013; accepted December 26, Liver transplantation is the standard of care for select patients with hepatocellular carcinoma (HCC) and cirrhosis. In response to high rates of recurrence and poor overall survival in the early years of transplantation, guidelines for transplantation for patients with HCC were developed. Most transplant centers in the international community use the Milan criteria to assess the candidacy of HCC patients for liver transplantation. 1 The 5-year survival rate for these patients exceeds 70%. Although the 5-year survival rate is robust for transplant patients within the Milan criteria, wait-list dropout remains a significant concern because of limited organ availability. HCC progression correlates with Abbreviations: HCC, hepatocellular carcinoma; MELD, Model for End-Stage Liver Disease; TACE, transarterial chemoembolization; TAE, transarterial embolization; UCSF, University of California San Francisco; UNOS, United Network for Organ Sharing. The authors of this article have no conflicts of interest to disclose as described by Liver Transplantation, and no funding was received. Address reprint requests to Michael D. Kluger, M.D., M.P.H., Department of Surgery, NewYork Presbyterian Hospital/Columbia Presbyterian Medical Center, 161 Fort Washington Avenue, New York, NY Telephone: ; FAX: ; mk2462@cumc.columbia.edu DOI /lt View this article online at wileyonlinelibrary.com. LIVER TRANSPLANTATION.DOI /lt. Published on behalf of the American Association for the Study of Liver Diseases VC 2014 American Association for the Study of Liver Diseases.

2 LIVER TRANSPLANTATION, Vol. 20, No. 5, 2014 KLUGER ET AL. 537 time, as does the risk of dropout from the wait list for medical and/or psychosocial reasons. Dropout rates range from 0% to 10% at 12 months according to cohort studies of T2 tumor patients from the last decade; rates as high as 40% at 12 months were previously reported. 2,3 One response has been the supplementation of Model for End-Stage Liver Disease (MELD) points for HCC based on the projected risk of tumor expansion beyond the Milan criteria. The United Network for Organ Sharing (UNOS) offers MELD exception points to patients who have tumors within the Milan criteria or whose tumors have been downsized by locoregional therapy to meet these criteria. However, in the United States, the benefit of MELD exception points varies by UNOS region. 4 Currently, 767 of 16,878 candidates listed for liver transplantation have a primary diagnosis of HCC. Twenty-five percent of these candidates have been listed for more than 1 year, and 53% have been waiting for longer than 6 months (according to Organ Procurement and Transplantation Network data as of April 20, 2012). Another strategy used to prevent progression on the wait list has been the use of embolic or ablative therapies. Among the available therapies, transarterial chemoembolization (TACE) has been used for more than a decade, and it is recommended by guidelines from both the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. 5-9 Bridging strategies with the aim of tumor destruction are considered to be beneficial for T2 patients waiting longer than 6 months. Both TACE and bland transarterial embolization (TAE) induce tumor necrosis at rates in the range of 16% to 60%. 10,11 TACE remains the more common practice while patients are awaiting transplantation despite the absence of convincing evidence of its superiority, and recognized toxicities. To provide further insight, we performed a retrospective, matched case-control study of patients undergoing TAE and TACE while awaiting transplantation. Equivalency between treatments was hypothesized. PATIENTS AND METHODS Patient Evaluation and Management The transplantation program provided care for candidates at 2 quaternary academic medical centers with more than 800 beds each. The same written protocols were used for patient evaluation and selection and postoperative management and surveillance. All patients were evaluated by a multidisciplinary team at the respective medical centers and were presented to a cross-campus selection committee; transplant hepatologists and surgeons cross-covered both medical centers. Patients with HCC were reviewed at a weekly conference of hepatologists, transplant surgeons, and diagnostic and interventional radiologists at which cross-sectional imaging was reviewed. All patients with appropriate hepatic reserves underwent bridging therapy if they were listed within the Milan criteria or if they met the University of California San Francisco (UCSF) criteria. 12 The determination of whether to pursue embolization or ablation was based on a consensus reached at the weekly conference. Because of institutional preferences, interventional radiologists at center A performed TACE, whereas interventional radiologists at center B performed TAE. All procedures were performed by interventional radiologists who were board-certified in diagnostic radiology, and fellowship-trained in interventional radiology at major transplantation centers. Because both centers were major referral centers for gastrointestinal disease and cancer, the interventional radiologists were very experienced with locoregional therapies. Scans were repeated approximately 1 month after an intervention and reviewed at conference to assess the need for further therapy, and they were repeated at 3-month intervals thereafter. During this study period, all transplant operations occurred at center A, and center A pathologists evaluated all specimens. Nonsurgical postoperative care and long-term HCC surveillance were conducted at each patient s preoperative medical center. Therefore, the major difference in the care received by patients with HCC between the 2 medical centers was the interventional radiology procedure performed. Intention-to-Treat Analysis All patients who underwent HCC embolization and were actively listed at centers A and B during the period of February 2002 to October 2010 were included in an intention-to-treat analysis with the Fine and Gray method for competing events. The entry date was the date of first embolization, and the treatment was defined as transplantation. Case-Control Groups, Measures, and Analyses A retrospective case-control study was performed. A review of a prospective database of all patients evaluated for liver transplantation was performed to identify patients with explant-confirmed HCC who had undergone bridging with transarterial therapies between February 2002 (the date of acceptance of the Milan criteria by UNOS) and October 2010; the first case meeting this criteria was performed in May A total of 25 patients with HCC were successfully bridged to transplantation with TAE. These patients were matched to transplant patients with explant-confirmed HCC after TACE during the same period in a 1:2 ratio according to the initial radiographic tumor size and number of tumors. Because the 25 TAE patients had unilobar disease at diagnosis, TACE patients with bilobar disease at diagnosis were excluded from the match to increase uniformity. The embolization decision was based on the tumor size, location, number, and the degree of underlying liver disease, with a total bilirubin level of 3 mg/dl usually serving as the cutoff for safe embolization.

3 538 KLUGER ET AL. LIVER TRANSPLANTATION, May 2014 TABLE 1. Wait-List Dropout Among All Patients With HCC Who Were Listed for Transplantation Between February 2002 and October 2010 Reason for Dropout n 5 25 n 5 3 Death due to complications 1 (4) of liver failure [n (%)] Death due to HCC 6 (24) progression [n (%)] HCC progression [n (%)] 10 (40) 1 (33) Too sick for transplantation [n (%)] 8 (32) 2 (67) The primary outcome measures were overall patient survival and recurrence-free survival. Overall survival was defined as the time from first embolization to death or last follow-up. Recurrence-free survival was defined as the time from first embolization to the recurrence of HCC after transplantation or death. Analyses are reported for 1 and 3 years because a small number of patients at center B had more than 4 years of data. Secondary outcome measures included the number of distinct embolization procedures and tumor necrosis according to explant pathology. Continuous variables are reported as means and standard deviations or as medians and interquartile ranges, and they were compared with the Student t test or Mann-Whitney-Wilcoxon test. To compare categorical variables, we used Pearson s v 2 test or Fisher s exact test. Time-to-event analyses were performed with the Kaplan-Meier method and the log-rank test. Repeated measures logistic regression was performed to assess longitudinal changes in tumors based on imaging and pathology and the Milan and UCSF criteria over time. A P value 0.05 was considered to indicate a statistically significant result. The institutional review board approved this protocol. Data were analyzed with Stata 11.2 (StataCorp, College Station, TX). RESULTS Population Patients During the study period, 1717 candidates in all from centers A and B were listed for transplantation, and 374 (22%) carried a primary or secondary diagnosis of HCC. A total of 256 listed patients underwent TAE (12%) or TACE (88%). Two hundred twenty of these patients underwent transplantation, 28 patients were delisted, and 8 patients were awaiting transplantation at the end of the period or were transferred to another center. The reasons for wait-list dropout are detailed in Table 1. Notably, 61% of the embolized patients who dropped off the wait list did so because of HCC progression or HCC-related death. On an intention-totreat basis, there was no significant risk of wait-list dropout associated with TAE or TACE (P ). Demographics for Case-Control Analyses The study population was primarily male (n 5 62 or 83%) and Caucasian (n 5 38 or 51%) and had a median age of 59 years (interquartile range years); there were no significant demographic differences between the TAE and TACE groups. Hepatitis C virus was the most common etiology for the underlying liver disease (Table 2). The mean laboratory MELD scores at transplantation were 9 6 6(median5 8, interquartile range ) for the TAE group and (median 5 9, interquartile range ) for the TACE group (P ). The mean MELD scores at transplantation with exception points were (median5 25, interquartile range ) for the TAE group and (median 5 22, interquartile range ) for the TACE group (P ). Sixty percent of the patients had MELD exception points: 17 TAE patients (68%) and 28 TACE patients (56%; P ) at the time of transplantation. Nine TAE patients (38%) and 27 TACE patients (55%) received transplants making use of extended-criteria grafts (P ). The mean time from the radiographic diagnosis to transplantation was months for the TAE group and months for the TACE group (P ); the study median was 9 months (interquartile range months; Table 3). The 2 groups were matched by tumor size and number (Table 3): the mean number of tumors was for the TAE group and for the TACE group, and the largest tumor was cm for the TAE group and cm for the TACE group. At the time of the radiographic diagnosis, 18 TAE patients (72%) and 34 TACE patients (68%) were within the Milan criteria (P ); 2 TAE patients (8%) and 3 TACE patients (6%) were within the UCSF criteria (P ); and the remainder were outside these criteria. More specifically, 1 tumor was beyond the UCSF criteria, and the 17 remaining lesions were too small to meet the Milan criteria. The time from first embolization to transplantation was months for the TAE group and months for the TACE group (P ). The overwhelming majority of the patients underwent a single transarterial procedure, with 16% of the TAE group (n 5 4) and 40% of the TACE group (n 5 20) undergoing 2 procedures and with 4% of the TAE group (n 5 1) and 2% of the TACE group (n 5 1) undergoing 4 procedures. Superselective embolization occurred during the first embolization procedure in 76% of the TAE cases (19/ 25) and in 92% of the TACE cases (45/49; P ), during the second embolization procedure in 75% of the TAE cases (3/4) and in 74% of the TACE cases (14/19; P ), during the third embolization procedure in 100% of the TAE cases (1/1) and in 100% of the TACE cases (2/2), and during the fourth embolization procedure in 100% of the TAE cases (1/1) and in 100% of the TACE cases (1/1). There were 2 crossovers from TAE to TACE, and there were no crossovers from TACE to TAE. One crossover occurred during the second chemoembolization, and the other occurred during the third chemoembolization; a clear rationale could

4 LIVER TRANSPLANTATION, Vol. 20, No. 5, 2014 KLUGER ET AL. 539 TABLE 2. Characteristics of 25 Patients Undergoing TAE and 50 Patients Undergoing TACE Who Were Matched by Tumor Size and Number on Initial Diagnostic Imaging: May 2002 to October 2010 TAE Group (n 5 25) TACE Group (n 5 50) P Value Demographics Age (years) Sex: male [n (%)] 22 (88) 40 (80) 0.39 Race [n (%)] White 13 (52) 25 (50) 0.45 Hispanic 4 (16) 14 (28) Black 3 (12) 2 (4) Other 5 (20) 9 (18) Underlying liver disease [n (%)] Hepatitis C virus 22 (88) 35 (70) 0.15 Other 3 (12) 15 (30) Diagnostic labs Total bilirubin (mg/dl) Platelets (10 9 /L) International normalized ratio Alpha-fetoprotein 200 lg/l [n (%)] 4 (16) 8 (16) 1.0 MELD score at transplantation Laboratory score Exception points Patients with exception points [n (%)] 17 (68) 28 (56) 0.32 Months to transplantation Radiographic diagnosis First embolization Listing not be determined for one of the patients, and the second patient was an inpatient at center A, which routinely performed TACE. All repeat embolizations treated local unilobar tumor recurrence except for 2 patients in the TACE group and 1 patient in the TAE group for whom new bilobar disease was treated. The particle size used for vessel stasis was identified for 97% of the 31 TAE interventions: 40 to 120 lm for 5 procedures (17%), 40 to 120 lm combined with 100 to 300 lm for 5 procedures (17%), 100 to 300 lm for 18 procedures (60%), and 300 to 500 lm for 2 procedures (6%). Ethiodol was used once (3%). The particle size used for vessel stasis was identified for 85% of the 73 TACE interventions: 40 to 120 lm for 3 procedures (6%), 100 to 300 lm for 54 procedures (87%), and 300 to 500 lm or larger for 5 procedures (7%). Adriamycin-based therapy was used for 100% of the total TACE procedures, and Ethiodol was used for 94% of these procedures. According to the imaging closest to transplantation, there were no significant differences in the tumor number or size (Table 3): the mean number of tumors was for the TAE group and for the TACE group (P ), and the largest tumor was cm for the TAE group and for the TACE group (P ). Eight percent of the patients in both groups now had bilobar disease (P ). Nineteen of the TAE patients (76%) and 34 of the TACE patients (68%) were within the Milan criteria (P ), and 1 member of the TAE group (2%) and 2 members of the TACE group (4%) were within the UCSF criteria. More specifically, 9 tumors were beyond the UCSF criteria, and 10 lesions remained too small to meet the Milan criteria. At explant, 14 of the TAE patients (58%) and 24 of the TACE patients (53%) were within the Milan criteria (P ); 1 patient in the TAE group (4%) and 3 patients in the TACE group (6%) were within the UCSF criteria (Table 3). The mean number of tumors was for the TAE group and for the TACE group (P ), and the largest tumor was cm for the TAE group and cm for the TACE group (P ). Longitudinal Analyses Patients were followed with serial imaging from the time of diagnosis through embolization and were compared on the basis of explant pathology. During the study period, 73% of the patients radiographically diagnosed within the Milan criteria remained within the Milan criteria according to explant findings. Moreover, 61% of the patients not diagnosed within the Milan criteria remained outside the Milan criteria at transplant. As for the UCSF criteria, 29% of the patients radiographically diagnosed within the UCSF criteria remained so according to explant findings. Moreover, 96% of the patients not diagnosed within the UCSF criteria remained outside the UCSF criteria at transplant. Transitions into or out of the

5 540 KLUGER ET AL. LIVER TRANSPLANTATION, May 2014 TABLE 3. Tumor Characteristics and Embolization Details for 25 Patients Undergoing TAE and 50 Patients Undergoing TACE Who Were Matched by Tumor Size and Number on Initial Diagnostic Imaging: May 2002 to October 2010 TAE Group (n 5 25) TACE Group (n 5 50) P Value Radiographic tumor characteristics at diagnosis Number of tumors [n (%)]* 1 15 (60) 33 (66) (32) 14 (28) 3 2 (8) 3 (6) Largest tumor diameter [n (%)]* <2 cm 9 (36) 18 (36) cm 14 (56) 28 (56) >5 cm 2 (8) 4 (8) Within Milan criteria [n (%)] 18 (72) 34 (68) 0.72 Within UCSF criteria [n (%)] 2 (8) 3 (6) 0.74 Arterial embolization Procedures before transplantation [n (%)] (96) 48 (96) (4) 2 (4) Pharmacological embolization at first intervention [n (%)] Adriamycin, cisplatin, mitomycin 0 47 (94) Adriamycin 0 3 (6) Ethiodol 1 (4) 40 (80) Radiographic tumor characteristics at transplant Number of tumors [n (%)] 1 12 (48) 35 (70) (40) 9 (18) 3 3 (12) 6 (12) Largest tumor diameter [n (%)] <2 cm 7 (28) 16 (32) cm 13 (52) 23 (46) >5 cm 5 (20) 11 (22) Bilobar [n (%)] 2 (8) 4 (8) 0.96 Within Milan criteria [n (%)] 19 (76) 34 (68) 0.45 Within UCSF criteria [n (%)] 1 (4) 2 (4) Explant tumor characteristics Number of tumors [n (%)] 1 15 (60) 36 (72) (24) 7 (14) 3 4 (16) 7 (14) Largest tumor diameter [n (%)] <2 cm 9 (36) 14 (28) cm 11 (44) 24 (48) >5 cm 5 (20) 12 (24) Complete tumor necrosis [n (%)] 9 (36) 13 (26) 0.37 Bilobar [n (%)] 4 (16) 5 (10) 0.45 Within Milan criteria [n (%)] 14 (56) 24 (48) 0.69 Within UCSF criteria [n (%)] 1 (4) 3 (6) Documented HCC recurrence after transplant [n (%)] 3 (12) 9 (18) 0.50 *Matching criteria. The data were too few for meaningful statistical comparisons. Milan (P ) or UCSF criteria (P ) were not significantly different between the TAE and TACE groups. Survival and Recurrence-Free Survival Analyses The rates of overall survival from the date of first embolization to death for transplant patients undergoing TAE were 96% (range 5 75%-99%) and 78% (range 5 55%- 90%) at 1 and 3 years, respectively (Fig. 1). The rates of overall survival from the date of first embolization to death for transplant patients undergoing TACE were 94% (range 5 82%-98%) and 74% (range 5 59%-85%) at 1 and 3 years, respectively. There was no significant difference (log-rank P ). The rates of recurrencefree survival from the date of first embolization to HCC recurrence for transplant patients undergoing TAE were 91% (range 5 70%-98%) and 72% (range 5 48%-87%) at

6 LIVER TRANSPLANTATION, Vol. 20, No. 5, 2014 KLUGER ET AL. 541 Figure 1. Overall survival of patients with HCC undergoing liver transplantation after TAE or TACE bridging therapy from the date of first embolization. Figure 2. Recurrence-free survival of patients with HCC undergoing liver transplantation after TAE or TACE bridging therapy from the date of first embolization. 1 and 3 years, respectively (Fig. 2). The rates of recurrence-free survival from the date of first embolization to HCC recurrence in transplant patients undergoing TACE were 92% (range 5 80%-97%) and 68% (range 5 51%-80%) at 1 and 3 years, respectively. There was no significant difference (log-rank P ). DISCUSSION Hepatic artery embolization of HCC is a validated palliative therapy for the treatment of patients with tumors too large to be treated by liver transplantation or too decompensated to be treated with resection. Transarterial therapy as a bridging therapy is supported by internationally recognized guidelines when the wait time exceeds 6 months. 8,9 As Seehofer et al. 13 recently summarized, transarterial therapy theoretically promotes control of tumor growth and vascular invasion, mitigates dropout during the waiting period, induces tumor necrosis to reduce tumor dissemination during transplantation, down-stages patients, and improves posttransplant outcomes by reducing the recurrence risk. These assertions come from the experiences of individual centers. In the current series, the mean time from the radiographic diagnosis to transplantation was 12 months, and this justified the program s tumor control strategy. With liver transplantation considered the intended treatment, an intention-to-treat analysis demonstrated no statistical difference between TACE and TAE as bridging therapies for the population of patients undergoing embolization for HCC. In other words, wait-list dropout due to progression or death related to HCC was not affected by the transarterial modality used at centers A and B. After matching for tumor size and number, no significant differences in the primary endpoints were identified for patients undergoing TACE and TAE. The overall 3-year survival rates were 78% and 74% for transplant patients undergoing TAE and TACE, respectively, and the 3-year recurrence-free survival rates were 72% and 68% for transplant patients undergoing TAE and TACE, respectively. In both groups, overall survival and recurrence-free survival were concordant with expected outcomes for patients within the Milan and UCSF criteria. 8,9,14,15 As a proxy of tumor progression or regression with respect to the embolization modality, longitudinal analyses were performed to assess movement along a continuum from T1 tumors (below the Milan criteria) to T2 tumors (the Milan criteria) to the UCSF criteria and beyond the UCSF criteria. There was movement within these groups from diagnostic imaging through postembolization imaging and explant pathology, but no significant differences were observed according to the use of TAE or TACE. Some of this movement may have been related to imaging, which has been demonstrated to both understage and overstage lesions in the range of 10% to 22%. 1,16-18 Both TAE and TACE induce tumor necrosis in up to 50% of treated patients, with objective responses noted in 16% to 60% of treated patients on crosssectional imaging. 9,19 The literature is conflicting about whether the addition of chemotherapeutics to the embolization agent enhances antitumoral effects, especially because there is currently no uniformity in agents, doses, or delivery mechanisms. 8,9,20 All explants were examined for tumor necrosis in the current study, and complete tumor necrosis was noted in 29% of the patients overall, with 36% in the TAE group and 26% in the TACE group (P ). Pathological reporting of partial necrosis was not uniform, so this was not included. These findings are reinforced by the American Association for the Study of Liver Diseases guidelines, which state that there are no differences between TAE and TACE. 9 In contrast, the European Association for the Study of the Liver guidelines, based on the same literature, discourage the use of TAE. 8 In a metaanalysis including 6 randomized controlled trials (3 of which directly compared TAE and TACE), TAE and TACE were found to be superior to the control. However, a sensitivity analysis showed a significant survival benefit with TACE versus the control but not with TAE. 19 The authors cautioned that this may have been an effect of the sample size, and in their

7 542 KLUGER ET AL. LIVER TRANSPLANTATION, May 2014 multicenter randomized control trial of TACE, TAE, and symptomatic management that was published 1 year later, they concluded that the results might have shifted the meta-analysis of TAE if it had been performed again. 10 In that study, TAE showed an advantage over the control, but the study was terminated before conclusive data could be collected. Other studies comparing TAE and TACE and also including drug-eluting beads, which are believed to provide controlled and sustained cytotoxic delivery, have also failed to demonstrate the superiority of TACE. 20,21 Neither center performed scheduled repetitive treatments. Repeat embolization was performed only for de novo lesions or when 1-month postembolization imaging showed residual disease. The average number of retreatments was consistent with historical reports in the range of 2 to 5. 9,10,18,19 However, patients receiving TACE were more than twice as likely to require 2 interventions. Underlying hepatic reserves based on total bilirubin levels and international normalized ratios were not significantly different between the groups, so an approach to prevent decompensation in the TACE patients with less aggressive first embolization does not explain this difference. 22 The trend toward fewer procedures in the TAE group may have cost implications: a recent study based on detailed Medicare costs from the Surveillance, Epidemiology, and End Results database estimated the cost per TACE procedure to be $24, Although we are unable to provide head-to-head cost data, embolization procedures are clearly costly, and fewer procedures would represent a cost reduction strategy. This study had limitations outside those related to its retrospective design. Pathology reports did not uniformly comment on the degree of tumor necrosis when multiple lesions were present. Therefore, tumor necrosis was reported in this analysis only when complete necrosis of all lesions was observed. The sample size was another potential limitation of this investigation. Center B contributed a smaller number of patients to the overall program volume, so there were case data for only 25 TAE patients. Although it can be argued that this limited the power to make a decision about therapy equivalency, the sample size was not remarkably different from the sample sizes of other studies informing decision making in this area. 8,9,11 Because of the disagreement in the literature about the longterm efficacy of TAE and TACE with respect to survival and recurrence-free survival, these findings cannot be generalized to patients not being bridged to transplantation within approximately a year of their diagnosis. Although other center biases may exist, they should be no more significant than those that would be observed in any multicenter study: all interventions were performed by highly trained and experienced specialists treating patients cared for and monitored by a single multidisciplinary team. In conclusion, the current study makes an important contribution to the literature by suggesting equivalency between TACE and TAE as bridges to transplantation. ACKNOWLEDGMENT The authors thank William Brubaker and Jonah Zaretsky for their efficient and accurate data collection efforts. REFERENCES 1. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334: Majno P, Lencioni R, Mornex F, Girard N, Poon RT, Cherqui D. Is the treatment of hepatocellular carcinoma on the waiting list necessary? Liver Transpl 2011; 17(suppl 2):S98-S Pereira SP, Williams R. Limits to liver transplantation in the UK. Gut 1998;42: Kadry Z, Schaefer EW, Uemura T, Shah AR, Schreibman I, Riley TR III. Impact of geographic disparity on liver allocation for hepatocellular cancer in the United States. J Hepatol 2012;56: Schaudt A, Kriener S, Schwarz W, Wullstein C, Zangos S, Vogl T, et al. Role of transarterial chemoembolization for hepatocellular carcinoma before liver transplantation with special consideration of tumor necrosis. Clin Transplant 2009;23(suppl 21): Spreafico C, Marchiano A, Regalia E, Frigerio LF, Garbagnati F, Andreola S, et al. Chemoembolization of hepatocellular carcinoma in patients who undergo liver transplantation. Radiology 1994;192: Majno PE, Adam R, Bismuth H, Castaing D, Ariche A, Krissat J, et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997;226: European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56: Bruix J, Sherman M; for American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53: Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37: Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004;127(suppl 1): S179-S Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33: Seehofer D, Nebrig M, Denecke T, Kroencke T, Weichert W, Stockmann M, et al. Impact of neoadjuvant transarterial chemoembolization on tumor recurrence and patient survival after liver transplantation for hepatocellular carcinoma: a retrospective analysis. Clin Transplant 2012;26: Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M, Miceli R, Mariani L. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl 2011;17(suppl 2):S44-S Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al.; for Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10:35-43.

8 LIVER TRANSPLANTATION, Vol. 20, No. 5, 2014 KLUGER ET AL Vauthey JN, Dixon E, Abdalla EK, Helton WS, Pawlik TM, Taouli B, et al.; for American Hepato-Pancreato- Biliary Association, Society of Surgical Oncology, and Society for Surgery of the Alimentary Tract. Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford) 2010;12: Libbrecht L, Bielen D, Verslype C, Vanbeckevoort D, Pirenne J, Nevens F, et al. Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transpl 2002;8: Yao FY, Kinkhabwala M, LaBerge JM, Bass NM, Brown R Jr, Kerlan R, et al. The impact of pre-operative locoregional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant 2005;5(pt 1): Llovet JM, Real MI, Monta~na X, Planas R, Coll S, Aponte J, et al.; for Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: Tsochatzis EA, Fatourou EM, Triantos CK, Burroughs AK. Transarterial therapies for hepatocellular carcinoma. Recent Results Cancer Res 2013;190: Malagari K, Pomoni M, Kelekis A, Pomoni A, Dourakis S, Spyridopoulos T, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010; 33: A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d Etude et de Traitement du Carcinome Hepatocellulaire. N Engl J Med 1995;332: Naugler WE, Sonnenberg A. Survival and costeffectiveness analysis of competing strategies in the management of small hepatocellular carcinoma. Liver Transpl 2010;16:

Reconsidering Liver Transplantation for HCC in a Era of Organ shortage

Reconsidering Liver Transplantation for HCC in a Era of Organ shortage Reconsidering Liver Transplantation for HCC in a Era of Organ shortage Professor Didier Samuel Centre Hépatobiliaire Inserm-Paris Sud Research Unit 1193 Departement Hospitalo Universitaire Hepatinov Hôpital

More information

HCC RADIOLOGIC DIAGNOSIS

HCC RADIOLOGIC DIAGNOSIS UCSF Transplant 2010 THE BEFORE AND AFTER HEPATOCELLULAR CARCINOMA MANAGEMENT Francis Yao, M.D. Professor of Clinical Medicine and Surgery Medical Director, Liver Transplantation University of California,

More information

HCC Imaging and Advances in Locoregional Therapy. David S. Kirsch MD Ochsner Clinic Foundation

HCC Imaging and Advances in Locoregional Therapy. David S. Kirsch MD Ochsner Clinic Foundation HCC Imaging and Advances in Locoregional Therapy David S. Kirsch MD Ochsner Clinic Foundation -Nothing to disclose Hepatic Imaging Primary imaging modalities include: US CT MR Angiography Nuclear medicine

More information

Surveillance for Hepatocellular Carcinoma

Surveillance for Hepatocellular Carcinoma Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April

More information

Guidelines for SIRT in HCC An Evolution

Guidelines for SIRT in HCC An Evolution Guidelines for SIRT in HCC An Evolution 2 nd Asia Pacific Symposium on Liver- Directed Y-90 Microspheres Therapy 1st November 2014, Singapore The challenge of HCC Surgery is potentially curative in early

More information

HCC: Is it an oncological disease? - No

HCC: Is it an oncological disease? - No June 13-15, 2013 Berlin, Germany Prof. Oren Shibolet Head of the Liver Unit, Department of Gastroenterology Tel-Aviv Sourasky Medical Center and Tel-Aviv University HCC: Is it an oncological disease? -

More information

Hepatocellular Carcinoma: Diagnosis and Management

Hepatocellular Carcinoma: Diagnosis and Management Hepatocellular Carcinoma: Diagnosis and Management Nizar A. Mukhtar, MD Co-director, SMC Liver Tumor Board April 30, 2016 1 Objectives Review screening/surveillance guidelines Discuss diagnostic algorithm

More information

hepatic artery chemoembolization (HACE) for hepatocellular Carcinoma in Patients Listed for Liver Transplantation

hepatic artery chemoembolization (HACE) for hepatocellular Carcinoma in Patients Listed for Liver Transplantation American Journal of Transplantation 2004; 4: 782 787 Blackwell Munksgaard Copyright C Blackwell Munksgaard 2004 doi: 10.1111/j.1600-6143.2004.00413.x Hepatic Artery Chemoembolization for Hepatocellular

More information

Despite recent advances in the care of patients with

Despite recent advances in the care of patients with Liver Transplantation for Hepatocellular Carcinoma: Lessons from the First Year Under the Model of End- Stage Liver Disease (MELD) Organ Allocation Policy Francis Y. Yao, 1,2 Nathan M. Bass, 1 Nancy L.

More information

Management of HepatoCellular Carcinoma

Management of HepatoCellular Carcinoma 9th Symposium GIC St Louis - 2010 Management of HepatoCellular Carcinoma Overview Pierre A. Clavien, MD, PhD Department of Surgery University Hospital Zurich Zurich, Switzerland Hepatocellular carcinoma

More information

Extending Indication: Role of Living Donor Liver Transplantation for Hepatocellular Carcinoma

Extending Indication: Role of Living Donor Liver Transplantation for Hepatocellular Carcinoma LIVER TRANSPLANTATION 13:S48-S54, 27 SUPPLEMENT Extending Indication: Role of Living Donor Liver Transplantation for Hepatocellular Carcinoma Satoru Todo, 1 Hiroyuki Furukawa, 2 Mitsuhiro Tada, 3 and the

More information

RESEARCH ARTICLE. Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment

RESEARCH ARTICLE. Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment DOI:10.22034/APJCP.2017.18.6.1697 RESEARCH ARTICLE Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment Alan Chuncharunee 1,

More information

WHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC?

WHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC? WHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC? Dr. Alexander Kim Chief, Vascular and Interventional Radiology, Medstar Georgetown University Hospital, USA DISCLAIMER Please note: The views

More information

Radiofrequency Ablation of Primary or Metastatic Liver Tumors

Radiofrequency Ablation of Primary or Metastatic Liver Tumors Radiofrequency Ablation of Primary or Metastatic Liver Tumors Policy Number: 7.01.91 Last Review: 9/2018 Origination: 2/1996 Next Review: 9/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC)

More information

Liver transplantation: Hepatocellular carcinoma

Liver transplantation: Hepatocellular carcinoma Liver transplantation: Hepatocellular carcinoma Alejandro Forner BCLC Group. Liver Unit. Hospital Clínic. University of Barcelona 18 de marzo 2015 3r Curso Práctico de Transplante de Órganos Sólidos Barcelona

More information

Hepatocellular Carcinoma: A major global health problem. David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center

Hepatocellular Carcinoma: A major global health problem. David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center Hepatocellular Carcinoma: A major global health problem David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center Hepatocellular Carcinoma WORLDWIDE The #2 Cancer Killer Overall cancer

More information

Living Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors?

Living Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors? Original Article Living Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors? R. F. Saidi 1 *, Y. Li 2, S. A. Shah 2, N. Jabbour 2 1 Division of Organ Transplantation, Department

More information

Total Tumor Volume and Alpha Fetoprotein for selection of transplant candidates. with hepatocellular carcinoma: a prospective validation

Total Tumor Volume and Alpha Fetoprotein for selection of transplant candidates. with hepatocellular carcinoma: a prospective validation Total Tumor Volume and Alpha Fetoprotein for selection of transplant candidates with hepatocellular carcinoma: a prospective validation Christian Toso 1, Glenda Meeberg 2, Roberto Hernandez-Alejandro 3,

More information

6/16/2016. Treating Hepatocellular Carcinoma: Deciphering the Clinical Data. Liver Regeneration. Liver Regeneration

6/16/2016. Treating Hepatocellular Carcinoma: Deciphering the Clinical Data. Liver Regeneration. Liver Regeneration Treating : Deciphering the Clinical Data Derek DuBay, MD Associate Professor of Surgery Director of Liver Transplant Liver Transplant and Hepatobiliary Surgery UAB Department of Surgery Liver Regeneration

More information

Liver Cancer: Diagnosis and Treatment Options

Liver Cancer: Diagnosis and Treatment Options Liver Cancer: Diagnosis and Treatment Options Fred Poordad, MD Chief, Hepatology University Transplant Center Professor of Medicine UT Health, San Antonio VP, Academic and Clinical Affairs, Texas Liver

More information

Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC

Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC Objectives Identify patient risk factors for hepatocellular carcinoma (HCC) Describe strategies

More information

Hepatobiliary Malignancies Retrospective Study at Truman Medical Center

Hepatobiliary Malignancies Retrospective Study at Truman Medical Center Hepatobiliary Malignancies 206-207 Retrospective Study at Truman Medical Center Brandon Weckbaugh MD, Prarthana Patel & Sheshadri Madhusudhana MD Introduction: Hepatobiliary malignancies are cancers which

More information

Selection Criteria and Insertion of SIRT into HCC Treatment Guidelines

Selection Criteria and Insertion of SIRT into HCC Treatment Guidelines Selection Criteria and Insertion of SIRT into HCC Treatment Guidelines 2 nd Asia Pacific Symposium on Liver- Directed Y-90 Microspheres Therapy 1st November 2014, Singapore Pierce Chow FRCSE PhD SIRT in

More information

NIH Public Access Author Manuscript J Surg Res. Author manuscript; available in PMC 2011 May 18.

NIH Public Access Author Manuscript J Surg Res. Author manuscript; available in PMC 2011 May 18. NIH Public Access Author Manuscript Published in final edited form as: J Surg Res. 2011 April ; 166(2): 189 193. doi:10.1016/j.jss.2010.04.036. Hepatocellular Carcinoma Survival in Uninsured and Underinsured

More information

9/10/2018. Liver Transplant for Hepatocellular Carcinoma (HCC): What is New? DISCLOSURES

9/10/2018. Liver Transplant for Hepatocellular Carcinoma (HCC): What is New? DISCLOSURES UCSF Transplant 2018: Pioneering Advances in Transplantation DISCLOSURES Liver Transplant for Hepatocellular Carcinoma (HCC): What is New? I have no relevant commercial interests or relationships to report

More information

Impact of cytolysis following transarterial chemoembolization for hepatocellular carcinoma

Impact of cytolysis following transarterial chemoembolization for hepatocellular carcinoma Original Article Impact of cytolysis following transarterial chemoembolization for hepatocellular carcinoma Vladimir Marquez 1, Marie-Pierre Sylvestre 2, Claire Wartelle-Bladou 3, Louis Bouchard 4, Pierre

More information

Transcatheter hepatic arterial chemoembolization may be considered medically necessary to

Transcatheter hepatic arterial chemoembolization may be considered medically necessary to Original Issue Date (Created): July 1, 2002 Most Recent Review Date (Revised): September 24, 2013 Effective Date: November 1, 2013 I. POLICY Hepatocellular carcinoma Transcatheter hepatic arterial chemoembolization

More information

INTRODUCTION. Journal of Surgical Oncology 2014;109:

INTRODUCTION. Journal of Surgical Oncology 2014;109: 2014;109:533 541 Transplant Versus Resection for the Management of Hepatocellular Carcinoma Meeting Milan Criteria in the MELD Exception Era at a Single Institution in a UNOS Region with Short Wait Times

More information

Optimizing Patient Selection, Organ Allocation, and Outcomes in Liver Transplant (LT) Candidates with Hepatocellular Carcinoma (HCC)

Optimizing Patient Selection, Organ Allocation, and Outcomes in Liver Transplant (LT) Candidates with Hepatocellular Carcinoma (HCC) XXVI SETH Congress- 30 November 2017 Optimizing Patient Selection, Organ Allocation, and Outcomes in Liver Transplant (LT) Candidates with Hepatocellular Carcinoma (HCC) Neil Mehta, MD University of California,

More information

21/02/2014. Disclosures. HCC: predicting recurrence. Outline. Liver transplant: Beyond Milan?

21/02/2014. Disclosures. HCC: predicting recurrence. Outline. Liver transplant: Beyond Milan? Disclosures HCC: predicting recurrence Peter Ghali, MD, FRCPC, MSc (epid) None relevant to this talk other than off-label use of sirolimus Toronto, February 2014 Outline Recurrence after what? Locoregional

More information

Liver Transplantation in Hepatocellular Carcinoma

Liver Transplantation in Hepatocellular Carcinoma Trends in Transplant. 2010;4:51-7 José Fuster, et al.: Liver Transplantation in Hepatocellular Carcinoma Liver Transplantation in Hepatocellular Carcinoma José Fuster, Constantino Fondevila, Santiago Sánchez,

More information

Treatment of Hepatocellular Carcinoma. Andrew J. Muir, MD MHS Division of Gastroenterology Duke University Medical Center

Treatment of Hepatocellular Carcinoma. Andrew J. Muir, MD MHS Division of Gastroenterology Duke University Medical Center Treatment of Hepatocellular Carcinoma Andrew J. Muir, MD MHS Division of Gastroenterology Duke University Medical Center Epidemiology of HCC: world The 5 th most common cancer worldwide > 500, 000 new

More information

Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)

Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Staff Reviewers: Dr. Yoo Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer

More information

TREATMENT FOR HCC AND CHOLANGIOCARCINOMA. Shawn Pelletier, MD

TREATMENT FOR HCC AND CHOLANGIOCARCINOMA. Shawn Pelletier, MD TREATMENT FOR HCC AND CHOLANGIOCARCINOMA Shawn Pelletier, MD Treatment for HCC Treatment strategies Curative first line therapy Thermal ablation vs Resection vs Transplant Other first line therapies TACE

More information

Hepatocellular Carcinoma: Transplantation, Resection or Ablation?

Hepatocellular Carcinoma: Transplantation, Resection or Ablation? Hepatocellular Carcinoma: Transplantation, Resection or Ablation? Roberto Gedaly MD Chief, Abdominal Transplantation Transplant Service Line University of Kentucky Nothing to disclose Disclosure Objective

More information

Selection of patients of hepatocellular carcinoma beyond the Milan criteria for liver transplantation

Selection of patients of hepatocellular carcinoma beyond the Milan criteria for liver transplantation Title Selection of patients of hepatocellular carcinoma beyond the Milan criteria for liver transplantation Author(s) Chan, SC; Fan, ST Citation Hepatobiliary Surgery and Nutrition, 2013, v. 2 n. 2, p.

More information

Transcatheter Arterial Chemoembolization (TACE) to Treat Primary or Metastatic Liver Malignancies. Original Policy Date

Transcatheter Arterial Chemoembolization (TACE) to Treat Primary or Metastatic Liver Malignancies. Original Policy Date MP 8.01.09 Transcatheter Arterial Chemoembolization (TACE) to Treat Primary or Metastatic Liver Malignancies Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date

More information

Hepatocellular Carcinoma. Markus Heim Basel

Hepatocellular Carcinoma. Markus Heim Basel Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749

More information

Interventional Radiologic Treatment of Hepatocellular Carcinoma

Interventional Radiologic Treatment of Hepatocellular Carcinoma Interventional Radiologic Treatment of Hepatocellular Carcinoma Fatih Boyvat Abstract The current treatment modalities for patients with hepatocellular carcinoma are discussed in this review. Hepatocellular

More information

Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis

Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis 2235-1795/16/0053-0175$39.50/0 175 Original Paper Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis Satoshi Kitai a Masatoshi Kudo a Naoshi Nishida a

More information

HPB ORIGINAL ARTICLE. Abstract. Keywords. Correspondence. Introduction

HPB ORIGINAL ARTICLE. Abstract. Keywords. Correspondence. Introduction DOI:1111/j.1477-2574.2009.00022.x HPB ORIGINAL ARTICLE Poorer survival in patients whose explanted hepatocellular carcinoma (HCC) exceeds Milan or UCSF Criteria. An analysis of liver transplantation in

More information

Locoregional Treatments for HCC Applications in Transplant Candidates. Locoregional Treatments for HCC Applications in Transplant Candidates

Locoregional Treatments for HCC Applications in Transplant Candidates. Locoregional Treatments for HCC Applications in Transplant Candidates Locoregional Treatments for HCC Applications in Transplant Candidates Matthew Casey, MD March 31, 2016 Locoregional Treatments for HCC Applications in Transplant Candidates *No disclosures *Off-label uses

More information

Transcatheter Arterial Chemoembolization (TACE) to Treat Primary or Metastatic Liver Malignancies

Transcatheter Arterial Chemoembolization (TACE) to Treat Primary or Metastatic Liver Malignancies Transcatheter Arterial Chemoembolization (TACE) to Treat Primary or Metastatic Liver Malignancies Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its

More information

SEQUENCING OF HCC TREATMENT. Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA

SEQUENCING OF HCC TREATMENT. Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA SEQUENCING OF HCC TREATMENT Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA February 2018 DISCLAIMER Please note: The views expressed within this presentation are the personal

More information

Locoregional Therapy for Hepatoma

Locoregional Therapy for Hepatoma Locoregional Therapy for Hepatoma Robert D. Crane, MD Interventional Radiology Virginia Mason How do we know a liver mass is HCC? HCC : Bx Of pts getting liver transplant only ~ 5% had Bx to establish

More information

Transcatheter Arterial Chemoembolization to Treat Primary or Metastatic Liver Malignancies

Transcatheter Arterial Chemoembolization to Treat Primary or Metastatic Liver Malignancies Transcatheter Arterial Chemoembolization to Treat Primary or Metastatic Liver Malignancies Policy Number: 8.01.11 Last Review: 6/2018 Origination: 8/2005 Next Review: 6/2019 Policy Blue Cross and Blue

More information

Liver Transplantation for Hepatocellular Carcinoma: Validation of the UCSF-Expanded Criteria Based on Preoperative Imaging

Liver Transplantation for Hepatocellular Carcinoma: Validation of the UCSF-Expanded Criteria Based on Preoperative Imaging American Journal of Transplantation 2007; 7: 2587 2596 Blackwell Munksgaard C 2007 The Authors Journal compilation C 2007 The American Society of Transplantation and the American Society of Transplant

More information

Medical Policy. MP Radiofrequency Ablation of Primary or Metastatic Liver Tumors

Medical Policy. MP Radiofrequency Ablation of Primary or Metastatic Liver Tumors Medical Policy MP 7.01.91 BCBSA Ref. Policy: 7.01.91 Last Review: 08/20/2018 Effective Date: 08/20/2018 Section: Surgery Related Policies 7.01.75 Cryosurgical Ablation of Primary or Metastatic Liver Tumors

More information

3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice

3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice 3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice Rome, 13 December 2013 Management and monitoring of HCC in the future era of DAA s Prof. Massimo Colombo Chairman Department of Liver,

More information

Once considered a relative contraindication to

Once considered a relative contraindication to Downstaging of Hepatocellular Cancer Before Liver Transplant: Long-Term Outcome Compared to Tumors Within Milan Criteria Francis Y. Yao, 1,2 Neil Mehta, 1 Jennifer Flemming, 1 Jennifer Dodge, 2 Bilal Hameed,

More information

This study received no grant or financial support, and none of the authors have any conflicts of interest to declare.

This study received no grant or financial support, and none of the authors have any conflicts of interest to declare. LIVER TRANSPLANTATION 20:912 921, 2014 ORIGINAL ARTICLE Pilot Study of High-Intensity Focused Ultrasound Ablation as a Bridging Therapy for Hepatocellular Carcinoma Patients Wait-Listed for Liver Transplantation

More information

Hepatocellular Carcinoma in Qatar

Hepatocellular Carcinoma in Qatar Hepatocellular Carcinoma in Qatar K. I. Rasul 1, S. H. Al-Azawi 1, P. Chandra 2 1 NCCCR, 2 Medical Research Centre, Hamad Medical Corporation, Doha, Qatar Abstract Objective The main aim of this study

More information

Trans-arterial radioembolisation (TARE) of unresectable HCC using Y-90 microspheres: is it dangerous in case of portal vein thrombosis?

Trans-arterial radioembolisation (TARE) of unresectable HCC using Y-90 microspheres: is it dangerous in case of portal vein thrombosis? Trans-arterial radioembolisation (TARE) of unresectable HCC using Y-90 microspheres: is it dangerous in case of portal vein thrombosis? Poster No.: C-1634 Congress: ECR 2014 Type: Authors: Keywords: DOI:

More information

Liver resection for HCC

Liver resection for HCC 8 th LIVER INTEREST GROUP Annual Meeting Cape Town 2017 Liver resection for HCC Jose Ramos University of the Witwatersrand Donald Gordon Medical Centre The liver is almost unique in that treatment of the

More information

Salvage Liver Transplantation for Recurrent Hepatocellular Carcinoma after Liver Resection: Retrospective Study of the Milan and Hangzhou Criteria

Salvage Liver Transplantation for Recurrent Hepatocellular Carcinoma after Liver Resection: Retrospective Study of the Milan and Hangzhou Criteria Salvage Liver Transplantation for Recurrent Hepatocellular Carcinoma after Liver Resection: Retrospective Study of the Milan and Hangzhou Criteria Zhenhua Hu 1,2,3, Jie Zhou 1,2,3, Zhiwei Li 1,2,3, Jie

More information

Post-embolization syndrome as an early predictor of overall survival after transarterial chemoembolization for hepatocellular carcinoma

Post-embolization syndrome as an early predictor of overall survival after transarterial chemoembolization for hepatocellular carcinoma DOI:10.1111/hpb.12487 HPB ORIGINAL ARTICLE Post-embolization syndrome as an early predictor of overall survival after transarterial chemoembolization for hepatocellular carcinoma Meredith C. Mason 1,2,

More information

IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?

IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views

More information

Liver Transplantation for HCC Which Criteria?

Liver Transplantation for HCC Which Criteria? Liver Transplantation for HCC Which Criteria? Jacques Belghiti - François Durand Claire Francoz Hepato-Biliary-Pancreatic Liver Surgery and Liver Transplantation Unit Hôpital Beaujon (AP-HP), Clichy -

More information

Clinical Study Transarterial Embolization for Hepatocellular Carcinoma: A Comparison between Nonspherical PVA and Microspheres

Clinical Study Transarterial Embolization for Hepatocellular Carcinoma: A Comparison between Nonspherical PVA and Microspheres BioMed Research International Volume 2015, Article ID 435120, 5 pages http://dx.doi.org/10.1155/2015/435120 Clinical Study Transarterial Embolization for Hepatocellular Carcinoma: A Comparison between

More information

Hepatocellular carcinoma

Hepatocellular carcinoma Hepatocellular carcinoma Mary Ann Y. Huang, M.D., M.S., FAASLD Transplant hepatologist Peak Gastroenterology Associates Porter Adventist Hospital Denver, Colorado Background - Worldwide Hepatocellular

More information

Liver Transplantation for Hepatocellular Carcinoma: An Appraisal of Current Controversies

Liver Transplantation for Hepatocellular Carcinoma: An Appraisal of Current Controversies 2235-1795/0014-0183$38.00/0 183 Review Liver Transplantation for Hepatocellular Carcinoma: An Appraisal of Current Controversies Yee Lee Cheah a Pierce K.H. Chow b,c,d a Hepatobiliary and Pancreatic Surgery,

More information

Multimodal therapy for hepatocellular carcinoma: A complementary approach to liver transplantation

Multimodal therapy for hepatocellular carcinoma: A complementary approach to liver transplantation ORIGINAL ARTICLE Multimodal therapy for hepatocellular carcinoma: a complementary approach to liver transplantation., 2010; 9 (1): 23-32 January-March, Vol. 9 No.1, 2010: 23-32 23 ABSTRACT Multimodal therapy

More information

Staging & Current treatment of HCC

Staging & Current treatment of HCC Staging & Current treatment of HCC Dr.: Adel El Badrawy Badrawy; ; M.D. Staging & Current ttt of HCC Early stage HCC is typically silent. HCC is often advanced at first manifestation. The selective ttt

More information

HCC surgical approach: resection and transplantation indications and outcome

HCC surgical approach: resection and transplantation indications and outcome SAMO, Friday 15th April 2011 Workshop on Primary liver tumors HCC surgical approach: resection and transplantation indications and outcome Gilles Mentha University Hospital of Geneva Hepatocellular Carcinoma

More information

100% pure beta emitter Decays to zirconium-90 Physical half-life of 64.1 hours (2.67 days) 94% of radiation delivered within 11 days

100% pure beta emitter Decays to zirconium-90 Physical half-life of 64.1 hours (2.67 days) 94% of radiation delivered within 11 days 100% pure beta emitter Decays to zirconium-90 Physical half-life of 64.1 hours (2.67 days) 94% of radiation delivered within 11 days TheraSphere [US package insert]. Surrey, UK: Biocompatibles UK Ltd,

More information

Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (ctace)

Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (ctace) Med Sci Monit, 2011; 17(4): 189-195 PMID: 21455104 WWW.MEDSCIMONIT.COM Clinical Research Received: 2010.08.04 Accepted: 2010.10.31 Published: 2011.04.01 Transarterial Chemoembolization of Child-A hepatocellular

More information

Waitlist Priority for Hepatocellular Carcinoma Beyond Milan Criteria: A Potentially Appropriate Decision Without a Structured Approach

Waitlist Priority for Hepatocellular Carcinoma Beyond Milan Criteria: A Potentially Appropriate Decision Without a Structured Approach American Journal of Transplantation 2014; 14: 79 87 Wiley Periodicals Inc. C Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/ajt.12530

More information

A) PUBLIC HEALTH B) PRESENTATION & DIAGNOSIS

A) PUBLIC HEALTH B) PRESENTATION & DIAGNOSIS Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary), April 2017 by Dr. Jenny Ko (Medical Oncologist, Abbotsford Centre, BC Cancer

More information

Paul Martin MD FACG. University of Miami

Paul Martin MD FACG. University of Miami Paul Martin MD FACG University of Miami 1 Liver cirrhosis of any cause Chronic C o c hepatitis epat t s B Risk increases with Male gender Age Diabetes Smoking ~5% increase in HCV-related HCC between 1991-28

More information

Hepatocellular carcinoma (HCC) is the third

Hepatocellular carcinoma (HCC) is the third Original Article / Transplantation Outcomes of loco-regional therapy for down-staging of hepatocellular carcinoma prior to liver transplantation Xian-Jie Shi, Xin Jin, Mao-Qiang Wang, Li-Xin Wei, Hui-Yi

More information

ACR Appropriateness Criteria Radiologic Management of Hepatic Malignancy EVIDENCE TABLE

ACR Appropriateness Criteria Radiologic Management of Hepatic Malignancy EVIDENCE TABLE Type 1. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 01;56():908-93.. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 011;53(3):100-10.

More information

Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Is There a Place for Resection?

Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Is There a Place for Resection? ORIGINAL ARTICLE Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Is There a Place for Resection? Elena Fernandez-Sevilla, 1 Marc-Antoine Allard, 1-3 Jasmijn Selten, 1 Nicolas Golse,

More information

Inverse relationship between cirrhosis and massive tumours in hepatocellular carcinoma

Inverse relationship between cirrhosis and massive tumours in hepatocellular carcinoma DOI:10.1111/j.1477-2574.2012.00507.x HPB ORIGINAL ARTICLE Inverse relationship between cirrhosis and massive tumours in hepatocellular carcinoma Umut Sarpel 1, Diego Ayo 2, Iryna Lobach 3, Ruliang Xu 4

More information

Due to the disparity between organ availability and

Due to the disparity between organ availability and Use of Sorafenib in Patients With Hepatocellular Carcinoma Before Liver Transplantation: A Cost-Benefit Analysis While Awaiting Data on Sorafenib Safety Alessandro Vitale, 1 Michael L. Volk, 2 Davide Pastorelli,

More information

SIR- RFS Journal Primer

SIR- RFS Journal Primer Comparison of Combina-on Therapies in the Management of Hepatocellular Carcinoma: Transarterial Chemoemboliza-on with Radiofrequency Abla-on versus Microwave Abla-on SIR- RFS Journal Primer Quick Summary

More information

Hepatocellular carcinoma: Options for diagnosing and managing a deadly disease

Hepatocellular carcinoma: Options for diagnosing and managing a deadly disease REVIEW CME CREDIT EDUCATIONAL OBJECTIVE: Readers will recognize the risk of hepatocellular carcinoma in patients with cirrhosis, regardless of the cause of the cirrhosis ARVIND R. MURALI, MD Department

More information

Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation

Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation Online Submissions: http://www.wjgnet.com/esps/ bpgoffice@wjgnet.com doi:10.3748/wjg.v19.i43.7515 World J Gastroenterol 2013 November 21; 19(43): 7515-7530 ISSN 1007-9327 (print) ISSN 2219-2840 (online)

More information

Comparison of Milan and UCSF criteria for liver transplantation to treat hepatocellular carcinoma

Comparison of Milan and UCSF criteria for liver transplantation to treat hepatocellular carcinoma Online Submissions: http://www.wjgnet.com/1007-9327office wjg@wjgnet.com doi:10.3748/wjg.v17.i37.4206 World J Gastroenterol 2011 October 7; 17(37): 4206-4212 ISSN 1007-9327 (print) ISSN 2219-2840 (online)

More information

A Novel Model Measuring the Harm of Transplanting Hepatocellular Carcinoma Exceeding Milan Criteria

A Novel Model Measuring the Harm of Transplanting Hepatocellular Carcinoma Exceeding Milan Criteria American Journal of Transplantation 2008; 8: 839 846 Blackwell Munksgaard C 2008 The Authors Journal compilation C 2008 The American Society of Transplantation and the American Society of Transplant Surgeons

More information

TACE: coming of age?

TACE: coming of age? Invasive procedures in the diagnosis and treatment of liver diseases: focal lesions F.Farinati Gastroenterologia, Padova TACE: coming of age? AISF 2005 TACE: LEVELS OF EVIDENCE Degree of certainty Methodology

More information

PATIENTS AND METHODS. Data Source

PATIENTS AND METHODS. Data Source LIVER TRANSPLANTATION 20:1045 1056, 2014 ORIGINAL ARTICLE Waiting Time Predicts Survival After Liver Transplantation for Hepatocellular Carcinoma: A Cohort Study Using the United Network for Organ Sharing

More information

Geographic Differences in Event Rates by Model for End-Stage Liver Disease Score

Geographic Differences in Event Rates by Model for End-Stage Liver Disease Score American Journal of Transplantation 2006; 6: 2470 2475 Blackwell Munksgaard C 2006 The Authors Journal compilation C 2006 The American Society of Transplantation and the American Society of Transplant

More information

3/22/2017. I will be discussing off label/investigational use of tivantinib for hepatocellular carcinoma.

3/22/2017. I will be discussing off label/investigational use of tivantinib for hepatocellular carcinoma. Grant/Research Support - AbbVie, Conatus, Hologic, Intercept, Genfit, Gilead, Mallinckrodt, Merck, Salix, Shire, Vital Therapies Consultant AbbVie, Gilead, Merck Member, Scientific Advisory Board Vital

More information

Current Concepts in Hepatocellular Carcinoma and Liver Transplantation: A Review and 2014 Update

Current Concepts in Hepatocellular Carcinoma and Liver Transplantation: A Review and 2014 Update REVIEW ARTICLE Current Concepts in Hepatocellular Carcinoma and Liver Transplantation: 10.5005/jp-journals-10018-1123 A Review and 2014 Update Current Concepts in Hepatocellular Carcinoma and Liver Transplantation:

More information

Transarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: Now and future

Transarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: Now and future pissn 2287-2728 eissn 2287-285X Review Clinical and Molecular Hepatology 2015;21:344-348 Transarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: Now and

More information

Clinical Study Use of Adjuvant Sorafenib in Liver Transplant Recipients with High-Risk Hepatocellular Carcinoma

Clinical Study Use of Adjuvant Sorafenib in Liver Transplant Recipients with High-Risk Hepatocellular Carcinoma Transplantation, Article ID 913634, 5 pages http://dx.doi.org/10.1155/2014/913634 Clinical Study Use of Adjuvant Sorafenib in Liver Transplant Recipients with High-Risk Hepatocellular Carcinoma Kirti Shetty,

More information

Surgical management of HCC. Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London

Surgical management of HCC. Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London Surgical management of HCC Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London Global distribution of HCC and staging systems WEST 1. Italy (Milan,

More information

DESCRIPTION OF PROCEDURE/SERVICE/PHARMACEUTICAL

DESCRIPTION OF PROCEDURE/SERVICE/PHARMACEUTICAL Subject: Transarterial Chemoembolization (TACE) for Primary Liver Hepatocellular Carcinoma (HCC) Original Effective Date: 10/31/2012 Policy Number: MCP-120 Revision Date(s): 7/16/2015 Review Date: 12/16/15,

More information

Feasibility Study of Transcatheter Arterial Chemoembolization with Epirubicin Drug-eluting Beads for Hepatocellular Carcinoma in Japanese Patients

Feasibility Study of Transcatheter Arterial Chemoembolization with Epirubicin Drug-eluting Beads for Hepatocellular Carcinoma in Japanese Patients Original Research Feasibility Study of Transcatheter Arterial Chemoembolization with Epirubicin Drug-eluting Beads for Hepatocellular Carcinoma in Japanese Patients 1) Department of Diagnostic Radiology,

More information

Liver Transplant Program, Chang Gung Memorial Hospital, Taoyuan 33378, Taipei, China

Liver Transplant Program, Chang Gung Memorial Hospital, Taoyuan 33378, Taipei, China Original Article Salvage transplantation for post-resection recurrence in hepatocellular carcinoma associated with hepatitis C virus etiology: a feasible strategy? Bhavin Bhupendra Vasavada 1, Chao-Long

More information

ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT

ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:989 994 ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT Level of -Fetoprotein Predicts Mortality Among Patients With Hepatitis C Related Hepatocellular

More information

80 Cancer Control. Special Report

80 Cancer Control. Special Report Special Report Cancer Control Journal of the Moffitt Cancer Center Transcatheter Arterial Chemoembolization and Percutaneous Ethanol Injection for Hepatocellular Carcinoma: A Retrospective Review of the

More information

Protocol. Transcatheter Arterial Chemoembolization to Treat Primary or Metastatic Liver Malignancies

Protocol. Transcatheter Arterial Chemoembolization to Treat Primary or Metastatic Liver Malignancies Transcatheter Arterial Chemoembolization to Treat Primary or (80111) Medical Benefit Effective Date: 07/01/13 Next Review Date: 03/18 Preauthorization Yes Review Dates: 09/09, 09/10, 03/11, 03/12, 05/12,

More information

Down-Staging of Hepatocellular Carcinoma via External-Beam Radiotherapy With Subsequent Liver Transplantation: A Case Report

Down-Staging of Hepatocellular Carcinoma via External-Beam Radiotherapy With Subsequent Liver Transplantation: A Case Report LIVER TRANSPLANTATION 19:1119 1124, 2013 ORIGINAL ARTICLE Down-Staging of Hepatocellular Carcinoma via External-Beam Radiotherapy With Subsequent Liver Transplantation: A Case Report Alan Wigg, 1,2 Kenneth

More information

Multidisciplinary Treatment Strategies for Primary and Metastatic Liver Cancers

Multidisciplinary Treatment Strategies for Primary and Metastatic Liver Cancers Multidisciplinary Treatment Strategies for Primary and Metastatic Liver Cancers Ching-Wei D. Tzeng, M.D. Assistant Professor Surgical Oncology University of Kentucky Markey Cancer Center Affiliate Network

More information

EASL-EORTC Guidelines

EASL-EORTC Guidelines Pamplona, junio de 2008 CLINICAL PRACTICE GUIDELINES: PARADIGMS IN MANAGEMENT OF HCC EASL-EORTC Guidelines Bruno Sangro Clínica Universidad de Navarra. CIBERehd. Pamplona, Spain Levels of Evidence according

More information

Wait Time for Curative Intent Radio Frequency Ablation is Associated with Increased Mortality in Patients with Early Stage Hepatocellular Carcinoma

Wait Time for Curative Intent Radio Frequency Ablation is Associated with Increased Mortality in Patients with Early Stage Hepatocellular Carcinoma ORIGINAL ARTICLE September-October, Vol. 16 No. 5, 2017: 765-771 765 The Official Journal of the Mexican Association of Hepatology, the Latin-American Association for Study of the Liver and the Canadian

More information

Long-term follow-up after conventional transarterial chemoembolization (c-tace) with mitomycin for hepatocellular carcinoma (HCC)

Long-term follow-up after conventional transarterial chemoembolization (c-tace) with mitomycin for hepatocellular carcinoma (HCC) Original Article Long-term follow-up after conventional transarterial chemoembolization (c-tace) with mitomycin for hepatocellular carcinoma (HCC) Ricardo Yamada, Beatriz Bassaco, Stephen Bracewell, Kirkpatrick

More information

Ioannis T. Konstantinidis, Yuman Fong. Introduction-general concepts

Ioannis T. Konstantinidis, Yuman Fong. Introduction-general concepts Review Article Page 1 of 10 Hepatocellular carcinoma in the modern era: transplantation, ablation, open surgery or minimally invasive surgery? A multidisciplinary personalized decision Ioannis T. Konstantinidis,

More information

Tumor incidence varies significantly, depending on geographical location.

Tumor incidence varies significantly, depending on geographical location. Hepatocellular carcinoma is the 5 th most common malignancy worldwide with male-to-female ratio 5:1 in Asia 2:1 in the United States Tumor incidence varies significantly, depending on geographical location.

More information